Neridronic acid – USA

Neridronic acid – USA

PGR decision: Jul. 28, 2020
AIA Review #
Filing Date
Institution Date
Petitioner
Patent
Respondent
Final Written Decision
PGR2019-00026
03/01/2019
07/30/2019
Grunenthal GmbH
9,931,352
Antecip Bioventures
All Claims Unpatentable
PGR2019-00027
03/01/2019
07/30/2019
Grunenthal GmbH
10,039,774
Antecip Bioventures
All Claims Unpatentable
PGR2019-00028
01/03/2019
08/20/2019
Grunenthal GmbH
10,052,338
Antecip Bioventures
All Claims Unpatentable
US  9,931,352 (ANTECIP BIOVENTURES II LLC): Non-OB
1. A method of treating hyperalgesia associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt form or an acid form to a human being suffering from hyperalgesia associated with complex regional pain syndrome.
17. A method of treating edema associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt form or an acid form to a human being suffering from edema associated with complex regional pain syndrome.
US  10,039,774 (ANTECIP BIOVENTURES II LLC): Non-OB
1. A method of treating changes in skin blood flow associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt or an acid form to a human being suffering from changes in skin blood flow associated with complex regional pain syndrome, wherein the human being has a pain intensity of at least 7 cm on the 10 cm visual analogue scale (VAS) or at least 7 on the 0-10 numerical rating scale (NRS).
16. A method of treating abnormal sudomotor activity associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt or an acid form to a human being suffering from abnormal sudomotor activity associated with complex regional pain syndrome, wherein the human being has a pain intensity of at least 7 cm on the 10 cm visual analogue scale (VAS) or at least 7 on the 0-10 numerical rating scale (NRS).
US  10,052,338 (ANTECIP BIOVENTURES II LLC): Non-OB
1. A method of treating allodynia associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt form or an acid form to a human being suffering from allodynia associated with complex regional pain syndrome.
17. A method of treating autonomic motor change associated with complex regional pain syndrome (CRPS), comprising administering neridronic acid in a salt form or an acid form to a human being suffering from autonomic motor change associated with CRPS.
Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved